Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

3SBio and DaVita Announce $20 Million Dialysis JV for China

publication date: Mar 9, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
3SBio will form a $20 million JV with DaVita Inc., a US-based company that owns and operates kidney dialysis clinics. The JV will provide dialysis services to Jilin and Liaoning provinces in northeast China. DaVita will contribute 70% of the start-up capital and 3SBio will be responsible for the remainder. As part of the agreement, the JV will use 3SBio’s EPAIO, a recombinant human erythropoietin, to treat the anemia that is often a side-effect of dialysis. More details....

Stock Symbols: (NSDQ: SSRX) (NYSE: DVA)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...